1 Correspondence Letter On March 6, 2023, The Lancet published an article titled “Inflammation and cholesterol as predictors of cardiovascular events among patients receiving statin therapy: a collaborative analysis of three randomized trials.” The study aimed to assess the relative importance of high-sensitivity C-reactive protein (CRP) and low-density lipoprotein cholesterol (LDL-C) as determinants of risk for major adverse cardiovascular events, cardiovascular death, and all-cause death among patients receiving statins [ 1 ]. The researchers performed a collaborative analysis of patients with or at high risk of atherosclerotic disease who were participants in the multinational PROMINENT, REDUCE-IT, or STRENGTH trials and were receiving contemporary statins. The article concluded that inflammation assessed by high-sensitivity CRP was a stronger predictor of future cardiovascular events and death than cholesterol assessed by LDL-C among patients receiving contemporary statins. While the article was well-written and reported interesting findings, we have several concerns regarding the analysis performed.